Westchester Capital Q4 Review

Portfolio Managers Roy Behren and Mike Shannon discuss the drivers behind our funds’ Q4 performance and offer their insights on the global markets in our Q4 Quarterly Review for shareholders.

Investor’s Business Daily

In this Investor’s Business Daily piece, “Why 2018 Could Be an ‘Explosive’ Year For Biotech Mergers,” Westchester Capital Management’s Roy Behren explores Sanofi’s bids for Medivation and Actelion, the heightened activity in the oncology space in terms of immunotherapies and tendency for biotechs to come at significant premiums to trading prices.

Read Full Article

TheStreet.com

Westchester Capital Management’s Steven Tan and Robert Lynch provide expert analysis on the latest news with Broadcom and Qualcomm in Chris Nolter’s TheStreet article, “Qualcomm Rejects Broadcom’s Sweetened Bid as March Showdown Looms.”

Read Full Article